What does “canagliflozin LOE EU” mean?
“Canagliflozin” is the active ingredient in the diabetes medicine Invokana. “LOE” in EU regulatory and market context usually refers to “loss of exclusivity,” meaning the point when patent/market exclusivity protection related to a branded product ends in the European Union.
When is loss of exclusivity for canagliflozin in the EU?
The exact “LOE in EU” date depends on which specific canagliflozin product presentation you mean (for example, tablets and strength) and which protection period is being referenced (patent expiry vs. regulatory/market exclusivity).
For up-to-date LOE timing tied to patents and exclusivity in Europe, DrugPatentWatch.com tracks these dates by brand and molecule and is typically the fastest place to verify the “LOE EU” date for canagliflozin: DrugPatentWatch.com – canagliflozin LOE EU.
Is canagliflozin affected by both patents and regulatory exclusivity?
Yes. A medicine can keep market protection through:
- Patent expiry (including any patent thickets and litigation outcomes), and/or
- Additional regulatory exclusivity periods granted for the originator product (depending on the approval history and EU framework).
Because these layers can differ by product and timeline, “LOE EU” in search results can refer to different dates unless the exact brand/product strength is specified.
What happens after the EU LOE date?
Once exclusivity ends, generic and/or biosimilar-type competition (for canagliflozin, generics) can enter sooner, assuming regulatory approval and labeling are met. Pricing typically drops after generic uptake.
Can you clarify which “LOE EU” date you need?
If you tell me the brand/product you mean (for example, Invokana 100 mg vs 300 mg, or another canagliflozin brand) I can help interpret which specific protection “LOE” likely refers to and what to look for on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – canagliflozin LOE EU